MedPath

HURO BIOTECH JOINT STOCK COMPANY

🇻🇳Vietnam
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

1 Phases

Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (100.0%)

Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis

Not Applicable
Completed
Conditions
Rhinosinusitis
Rhinitis
Interventions
Combination Product: Bacillus subtilis DSM32444
Drug: Neomycin/ Dexameythasone/Xylometazoline
First Posted Date
2023-08-21
Last Posted Date
2024-03-05
Lead Sponsor
Huro Biotech Joint Stock Company
Target Recruit Count
60
Registration Number
NCT05999955
Locations
🇻🇳

Thai Binh University of Medicine and Pharmacy, Thái Bình, Thai Binh, Vietnam

Safety Evaluation of Intranasal Use of DSM 32444 Postbiotic in Humans

Not Applicable
Completed
Conditions
Rhino Sinusitis
Interventions
Drug: 0.9% NaCl isotonic saline solution
Combination Product: Bacillus subtilis DSM32444, inactivated
First Posted Date
2023-08-09
Last Posted Date
2024-04-12
Lead Sponsor
Huro Biotech Joint Stock Company
Target Recruit Count
60
Registration Number
NCT05984004
Locations
🇻🇳

Thai Binh University of Medicine and Pharmacy, Thái Bình, Thai Binh, Vietnam

News

No news found
© Copyright 2025. All Rights Reserved by MedPath